Selective Nicotinic Acetylcholine Receptor Antagonists for Peripheral Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for small and non-small cell lung cancer, HIV, cognitive disorders, and neurodegenerative diseases like Alzheimer's lack effective compounds that specifically target nicotinic acetylcholine receptors, leading to inadequate therapeutic options and significant health challenges.
Innovation Solution
Development of novel nicotinic acetylcholine receptor antagonists with selective α7 nAChR binding properties, which are less lipophilic and polar, reducing the likelihood of crossing the Blood-Brain Barrier and causing central nervous system side effects, allowing for potent activity in the peripheral nervous system while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If selective α7 nAChR antagonists are designed to be less lipophilic and more polar, then the likelihood of crossing the Blood-Brain Barrier is reduced, minimizing central nervous system side effects, but the ability to cross the Blood-Brain Barrier for treating central nervous system disorders is compromised
Solution Approach 1:
The patent applies parameter changes by systematically modifying the lipophilicity and polarity parameters of the antagonist compounds. By adjusting these physicochemical parameters, the compounds achieve reduced blood-brain barrier penetration (lowering CNS side effects) while maintaining or enhancing peripheral nAChR antagonism. This is accomplished through structural modifications that control the balance between lipophilicity and polarity.
2Reliability
If existing antagonists like α-BTX and MLA are used, then potent α7 nAChR antagonism is achieved, but off-target inhibition of muscle-type nAChRs and other subtypes (α9, α9α10) occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that confer selectivity for α7 nAChR over other subtypes. The molecular structure incorporates particular functional groups and spatial arrangements that create local interaction characteristics matching the α7 receptor binding site, while avoiding interactions with muscle-type and other neuronal nAChR subtypes. This enables potent and selective α7 antagonism without off-target effects.
3Reliability
If compounds are designed for high potency in peripheral nervous system, then effective treatment of peripheral diseases (cancer, HIV) is achieved, but central nervous system toxicity increases
Solution Approach 1:
The patent resolves this contradiction by changing the lipophilicity parameter of the compounds. By reducing lipophilicity and increasing polarity, the compounds maintain high potency at peripheral nAChR targets while their reduced ability to penetrate the lipophilic blood-brain barrier inherently limits central nervous system exposure and toxicity. This parameter optimization achieves the desired therapeutic window.
Data Source
AI summary
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.